Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2020-02-19
- Target Recruit Count
- 31
- Registration Number
- NCT00440726
- Locations
- 🇨🇦
Sick Kids, Toronto, Ontario, Canada
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 77
- Registration Number
- NCT00433537
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2006-12-14
- Lead Sponsor
- International BFM Study Group
- Target Recruit Count
- 2600
- Registration Number
- NCT00411541
- Locations
- 🇦🇷
Department of Pediatric Hematology-Oncology, Italian Hospital, Buenos Aires, Argentina
🇧🇪Department of Pediatric Hemato-Oncology, Gent University Hospital, Gent, Belgium
🇦🇹Children's Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00410488
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT00390793
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
- Conditions
- Interventions
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT00379574
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷Asan Medical Cener, Seoul, Korea, Republic of
Ph II CHOP+Velcade in Mediastinal LBCL
- Conditions
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00361621
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00352027
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 26
- Registration Number
- NCT00335140
- Locations
- 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
🇺🇸Bronson Methodist Hospital, Kalamazoo, Michigan, United States
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2006-09-26
- Lead Sponsor
- The Alvin and Lois Lapidus Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00333008
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Northwest Hospital Center, Randallstown, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.